Rein Therapeutics, Inc. SEC filings RNTX
Rein Therapeutics, Inc. has 525 filings in SEC EDGAR's recent list, going back to Dec 3, 2007. Its latest annual report, Form ARS, was filed on Jun 8, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 4, 2026 (regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Apr 30, 2026 | — |
| CORRESP | Letter to the SEC | Apr 28, 2026 | — |
| CORRESP | Letter to the SEC | Apr 28, 2026 | — |
| UPLOAD | Letter from the SEC | Dec 31, 2025 | — |
| DRS | Filing | Dec 29, 2025 | — |
| EFFECT | Filing | Sep 5, 2025 | — |
| CORRESP | Letter to the SEC | Sep 4, 2025 | — |
| UPLOAD | Letter from the SEC | Sep 4, 2025 | — |
| EFFECT | Filing | May 22, 2025 | — |
| CORRESP | Letter to the SEC | May 21, 2025 | — |
| UPLOAD | Letter from the SEC | May 21, 2025 | — |
| NT 10-K | Filing | Mar 31, 2025 | Dec 31, 2024 |
| NT 10-K | Filing | Apr 1, 2024 | Dec 31, 2023 |
| EFFECT | Filing | Feb 5, 2024 | — |
| CORRESP | Letter to the SEC | Feb 1, 2024 | — |
| UPLOAD | Letter from the SEC | Feb 1, 2024 | — |
| D | Filing | Nov 16, 2023 | — |
| EFFECT | Filing | Jun 16, 2022 | — |
| CORRESP | Letter to the SEC | Jun 14, 2022 | — |
| UPLOAD | Letter from the SEC | Jun 14, 2022 | — |
| DEL AM | Filing | Jun 13, 2022 | — |
| EFFECT | Filing | Feb 9, 2021 | — |
| CORRESP | Letter to the SEC | Feb 5, 2021 | — |
| UPLOAD | Letter from the SEC | Feb 4, 2021 | — |
| EFFECT | Filing | Oct 15, 2020 | — |
| CORRESP | Letter to the SEC | Oct 13, 2020 | — |
| UPLOAD | Letter from the SEC | Oct 8, 2020 | — |
| EFFECT | Filing | Aug 21, 2020 | — |
| CORRESP | Letter to the SEC | Aug 19, 2020 | — |
| UPLOAD | Letter from the SEC | Aug 18, 2020 | — |
| CT ORDER | Filing | Jun 12, 2020 | — |
| EFFECT | Filing | Jul 16, 2019 | — |
| EFFECT | Filing | Jul 15, 2019 | — |
| CORRESP | Letter to the SEC | Jul 11, 2019 | — |
| UPLOAD | Letter from the SEC | May 23, 2019 | — |
| EFFECT | Filing | May 14, 2019 | — |
| CORRESP | Letter to the SEC | May 10, 2019 | — |
| UPLOAD | Letter from the SEC | May 7, 2019 | — |
| UPLOAD | Letter from the SEC | Aug 15, 2018 | — |
| CT ORDER | Filing | Jun 29, 2017 | — |
| EFFECT | Filing | Jun 28, 2017 | — |
| CORRESP | Letter to the SEC | Jun 26, 2017 | — |
| CORRESP | Letter to the SEC | Jun 26, 2017 | — |
| CERTNAS | Auto-generated paper document | Jun 23, 2017 | — |
| 8-A12B | Filing | Jun 23, 2017 | — |
| CORRESP | Letter to the SEC | Jun 19, 2017 | — |
| CORRESP | Letter to the SEC | Jun 7, 2017 | — |
| DRSLTR | Filing | May 26, 2017 | — |
| DRS/A | Filing | May 26, 2017 | — |
| UPLOAD | Letter from the SEC | May 12, 2017 | — |
| DRS/A | Filing | Apr 17, 2017 | — |
| D | Filing | Jan 6, 2017 | — |
| DRS/A | Filing | Mar 28, 2016 | — |
| DRS/A | Filing | Dec 29, 2015 | — |
| DRSLTR | Filing | Dec 29, 2015 | — |
| UPLOAD | Letter from the SEC | Oct 5, 2015 | — |
| DRS | Filing | Sep 10, 2015 | — |
| D | Filing | Oct 29, 2014 | — |
| D | Filing | Nov 19, 2013 | — |
| D | Filing | Jun 12, 2009 | — |
| REGDEX/A | Auto-generated paper document | Apr 23, 2008 | — |
| REGDEX | Auto-generated paper document | Dec 3, 2007 | — |
Showing 62 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- RNTX (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Austin, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1420565
- Former names
- Aileron Therapeutics, Inc. (until Dec 9, 2024); AILERON THERAPEUTICS INC (until Mar 29, 2024)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.